Recent News

• 09.16.2025 - Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
• 09.11.2025 - Lucid Diagnostics Announces Closing of Public Offering of Common Stock
• 09.10.2025 - Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
• 09.09.2025 - Lucid Diagnostics Announces Proposed Public Offering of Common Stock
• 09.05.2025 - Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025
• 08.27.2025 - Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
• 08.13.2025 - Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
• 08.05.2025 - Lucid Diagnostics to Participate in Upcoming Investor Conferences
• 07.30.2025 - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
• 07.16.2025 - MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

Recent Filings

• 09.11.2025 - EX-99.1 EX-99.1
• 09.11.2025 - 8-K Current report
• 09.10.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 09.10.2025 - EX-99.1 EX-99.1
• 09.10.2025 - 8-K Current report
• 09.09.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 08.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.13.2025 - 8-K Current report
• 08.13.2025 - EX-99.1 EX-99.1
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]